PMID- 35429525
OWN - NLM
STAT- MEDLINE
DCOM- 20220608
LR  - 20220621
IS  - 1573-2517 (Electronic)
IS  - 0165-0327 (Linking)
VI  - 310
DP  - 2022 Aug 1
TI  - Acceptability, safety and tolerability of antidepressant repetitive transcranial 
      magnetic stimulation for adolescents: A mixed-methods investigation.
PG  - 43-51
LID - S0165-0327(22)00395-0 [pii]
LID - 10.1016/j.jad.2022.04.057 [doi]
AB  - OBJECTIVE: Major depressive disorder (MDD) is relatively common in adolescence, 
      with far-reaching impacts. Current treatments frequently fail to alleviate 
      depression severity for a substantial portion of adolescents. Repetitive 
      transcranial magnetic stimulation (rTMS) may assist with this unmet clinical 
      need. However, little is known about adverse events (AEs) experienced by 
      adolescents receiving rTMS, subjective treatment experiences of adolescents and 
      their parents, or treatment acceptability. METHODS: Fourteen adolescents 
      (16.5 years +/- 1.2; 71.4% female) with MDD received 20 sessions of either 
      high-frequency (10 Hz; n = 7) left dorsolateral prefrontal cortex (DLPFC) or 
      low-frequency (1 Hz; n = 7) right DLPFC rTMS. AEs were monitored at baseline and 
      at weekly intervals via New York State Psychiatric Institute Side Effects Form 
      for Children and Adolescents. Eight adolescents and nine parents participated in 
      interviews regarding subjective treatment experience, analysed via content 
      analysis. RESULTS: Drowsiness and lethargy were common AEs, reported by 92.3% of 
      participants in week one. Number of AEs decreased throughout treatment course 
      (after 5 treatments: M = 11.23, SD = 5.00; after 20 treatments: M = 8.92, 
      SD = 5.95). Thirty-five AEs emerged during treatment, most commonly transient 
      dizziness. Frequency, severity, and number of AEs reported were equivalent 
      between treatment groups. Treatment adherence and satisfaction were high. 
      Qualitative findings identified three themes relating to rTMS experience: 
      Preparation and connection; Physical experience of treatment; and Perceived role 
      of treatment. LIMITATIONS: Sample size was small, therefore findings are 
      preliminary. CONCLUSIONS: rTMS was an acceptable treatment for adolescent MDD, 
      from both adolescents' and parents' perspectives, and was safe and 
      well-tolerated, as AE frequency and type did not differ from rTMS treatment 
      courses in adults.
CI  - Copyright (c) 2022 Elsevier B.V. All rights reserved.
FAU - Wallman, Emily Jean
AU  - Wallman EJ
AD  - Centre for Developmental Psychiatry and Psychology, Department of Psychiatry, 
      School of Clinical Sciences at Monash Health, Monash University, Clayton, 
      Victoria, Australia. Electronic address: emily.wallman@monash.edu.
FAU - Segrave, Rebecca Anne
AU  - Segrave RA
AD  - BrainPark, Turner Institute for Brain and Mental Health, Monash University, 
      Clayton, Victoria, Australia.
FAU - Gordon, Michael Solomon
AU  - Gordon MS
AD  - Centre for Developmental Psychiatry and Psychology, Department of Psychiatry, 
      School of Clinical Sciences at Monash Health, Monash University, Clayton, 
      Victoria, Australia; Early in Life Mental Health Service, Monash Health, Clayton, 
      Victoria, Australia.
FAU - Fraser, Maxwell James Oliver Barnett
AU  - Fraser MJOB
AD  - Early in Life Mental Health Service, Monash Health, Clayton, Victoria, Australia.
FAU - Pavlou, Chris
AU  - Pavlou C
AD  - Early in Life Mental Health Service, Monash Health, Clayton, Victoria, Australia.
FAU - Melvin, Glenn Alexander
AU  - Melvin GA
AD  - School of Psychology, Faculty of Health, Deakin University, Burwood, Victoria, 
      Australia; Centre for Educational Development, Appraisal & Research, University 
      of Warwick, Coventry, UK.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20220414
PL  - Netherlands
TA  - J Affect Disord
JT  - Journal of affective disorders
JID - 7906073
RN  - 0 (Antidepressive Agents)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Antidepressive Agents/therapeutic use
MH  - Child
MH  - *Depressive Disorder, Major/drug therapy
MH  - Female
MH  - Humans
MH  - Male
MH  - Prefrontal Cortex/physiology
MH  - *Transcranial Magnetic Stimulation/adverse effects/methods
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Adolescent depression
OT  - Adverse events
OT  - Treatment acceptability
OT  - Treatment satisfaction
OT  - rTMS
EDAT- 2022/04/17 06:00
MHDA- 2022/06/09 06:00
CRDT- 2022/04/16 20:09
PHST- 2021/10/09 00:00 [received]
PHST- 2022/02/21 00:00 [revised]
PHST- 2022/04/10 00:00 [accepted]
PHST- 2022/04/17 06:00 [pubmed]
PHST- 2022/06/09 06:00 [medline]
PHST- 2022/04/16 20:09 [entrez]
AID - S0165-0327(22)00395-0 [pii]
AID - 10.1016/j.jad.2022.04.057 [doi]
PST - ppublish
SO  - J Affect Disord. 2022 Aug 1;310:43-51. doi: 10.1016/j.jad.2022.04.057. Epub 2022 
      Apr 14.